Estela Rodriguez: Keeping up with the press-release literature pre-ASCO24

Estela Rodriguez shared on X:

“Keeping up with the press-release literature pre-ASCO24.

TROPION-lung01 Datopotamab deruxtecan (ADC) showed meaningful (magnitude?) OS advantage vs. chemo in the subgroup of non-squamous NSCLC (but not overall population).” .

Source: Estela Rodriguez/X

Estela Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials. Dr. Rodriguez is known to help empower women to take charge of their own healthcare and believes in the power of mentorship.